Dermatology Times, May 2024 (Vol. 45. No. 05)

It is important dermatologists learn to recognize the clinical findings of dermatophytomas and distinguish them from other onychomycosis subtypes because the recommended treatments differ.

Clinicians, especially those who see patients with inflammatory and pigmentary disorders, should incorporate alcohol use disorder screening measures into all patient visits.

In this month’s Cosmetic Conundrums column, explore what dermatology clinicians need to know about false eyelashes to help prevent infections or contact dermatitis.

Mark Lebwohl, MD, and Saakshi Khattri, MD, discuss the evolving landscape of plaque psoriasis treatments over the past year.

5 experts share insights on long-term safety, efficacy, demographic variances, and more in pediatric AD.

Leading dermatologists explore key benchmarks, emerging trends, personalized medicine approaches, and more in atopic dermatitis.

A prebiotic cleanser and moisturizer regimen not only significantly alleviated the severity of atopic dermatitis and xerosis, but also uncovered crucial differences in symptom experiences.

Dermatology Times' Spring Editor in Chief, Aaron Farberg, MD, discusses the business strategy known as buy and bill.

The Harris brothers serve 2 predominantly elderly populations and appreciate the opportunity to provide solutions for the growing complexity of skin cancer issues as patients live longer.

Our May issue of Dermatology Times spotlights melanoma/skin cancer awareness and more.

This recap of skin cancer innovations accompanies the cover story of our May publication.

Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.

The FDA has released guidelines for clinicians and tips to identify the distinguishing features of counterfeit products.

Risankizumab demonstrated the highest efficacy in PASI90 responses among analyzed IL-23 inhibitors.

This week’s collection of the latest dermatologic studies covers circulating tumor DNA in advanced cSCC, targeting IL-13 with tralokinumab in AD, a pediatric lymphoplasmocytic plaque case report, and skin of color reporting in randomized controlled trials focusing on SCC.

This week’s collection of the latest dermatologic studies covers topical permethrin 5% vs. benzyl benzoate 25% for scabies, the safety of omalizumab in CSU during pregnancy, symptoms of cognitive impairment in children with AD, and the ethics of cosmetic overtreatment.

Over 50% of women in their 20s and over 35% of women aged 30 to 39 years struggle with adult female cystic acne.

It is always essential to have clear communication regarding expectations at your new practice.